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Abstract
 
Cylindromas are benign adnexal skin tumors caused by germline mutations in the CYLD gene.
In most cases the second wild-type allele is lost in tumor tissue, suggesting that CYLD functions
as tumor suppressor. CYLD is a protein of 956 amino acids harboring a functional deubiqui-
tinating domain at the COOH-terminal end. To shed more light on the function of CYLD,
we have performed a yeast two hybrid screen using an HaCaT cDNA library that identified the
RING finger protein TRIP (TRAF-interacting protein) as interactor with full-length CYLD.
Mapping of the interacting domains revealed that the central domain of CYLD binds to the
COOH-terminal end of TRIP. Far Western analysis and coimmunoprecipitations in mammalian
cells confirmed that full-length CYLD binds to the COOH-terminal domain of TRIP. Because
TRIP is an inhibitor of nuclear factor (NF)-
 

 
B activation by tumor necrosis factor (TNF), the
effect of CYLD on NF-
 

 
B activation was investigated in HeLa cells. The results established
that CYLD down-regulates NF-
 

 
B activation by TNF-
 

 
. The inhibition by CYLD depends
on the presence of the central domain interacting with TRIP and its deubiquitinating activity.
These findings indicate that cylindromas arise through constitutive NF-
 

 
B activation leading to
hyperproliferation and tumor growth.
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Introduction
 
Cylindromas are benign adnexal tumors that most likely
arise from the eccrine or apocrine cells of the skin (1, 2).
They emerge in the second or third decade of life in hairy
areas of the body, but never on the palms and soles where
apocrine glands are absent (3). They accumulate in number
and grow slowly throughout life, sometimes forming a con-
fluent disfiguring mass on the scalp (turban tumor syn-
drome). The familial form of cylindromatosis is inherited as
an autosomal dominant predisposition to multiple adnexal
skin tumors which has been mapped to chromosome
16q12-13 by genetic linkage analysis (4–8). Mutational
analysis in genes localized to the candidate interval revealed
mutations in a single gene, CYLD, in both the germline of
21 cylindromatosis families and sporadic cylindromatosis
cases (9). Most of the mutations are premature stop codons
leading to proteins truncated in the second half of the protein.
Genetic data indicate that CYLD is a tumor suppressor gene
(4, 7, 10). There are no indications that CYLD inactivation
leads to chromosomal instability (9). Abrogation of CYLD
alleles could promote neoplastic transformation by promoting
cell proliferation and/or inhibition of apoptosis.
The CYLD gene is expressed ubiquitously, which seems
to be difficult to reconcile with the localized body distribution
of cylindromas. The protein encoded by the CYLD gene
comprises 956 amino acids (aa; reference 9). Protein motif
searches (9) of CYLD revealed three regions in the NH
 
2
 
-
terminal half exhibiting weak homology to a glycine-rich
region found in some cytoskeleton-associated proteins
(CAP-Gly domain; reference 11). The COOH-terminal
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part of CYLD displays partial homology to the active sites
of ubiquitin-specific proteases (12, 13). This enzymatic ac-
tivity of CYLD was confirmed by a chemistry-based ap-
proach (14), indicating that CYLD could deubiquitinate
target proteins.
To elucidate the functional role of CYLD at the molec-
ular and cellular level in adnexal tumor suppression, we
sought to determine molecular partners of CYLD. This
identified TRIP (TRAF-interacting protein) as a CYLD
interactor, and reporter assays demonstrated an inhibitory
role of CYLD in TNF-
 

 
–mediated nuclear factor (NF)-
 

 
B
activation. This suggests that loss of CYLD leads to deregu-
lation of NF-
 

 
B signaling giving rise to neoplasia in epi-
dermal adnexal tissue.
 
Materials and Methods
 
Yeast Two Hybrid Screen.
 
Full-length and partial cDNAs en-
coding CYLD and candidate proteins were cloned into the
pGBKT7 or pGADT7 vectors (CLONTECH Laboratories,
Inc.), respectively. Screening for interactors was performed in the
AH109 yeast strain on high stringency plates (SD/-ade-his-
leu-trp, 10 mM 3-amino-1,2,4-triazole, 20 
 

 
g/ml 5-bromo-
4-chloro-3-indolyl-
 

 
-D-galactopyranoside). Activity of 
 

 
-galac-
tosidase in culture medium was measured with para-nitrophenol-
 

 
-galactopyranoside (Sigma-Aldrich). Candidate clones and
constructs were analyzed by sequencing.
 
Mammalian Cell Expression.
 
pCYLD1 and pCruzCYLD1
were constructed by insertion of full-length CYLD cDNA either
in pMT2 (15) or pCruzHA vector (Santa Cruz Biotechnology,
Inc.) to express proteins NH
 
2 
 
terminally tagged with FLAG or
HA, respectively. Premature stop codons were introduced by
PCR. Complete TRIP cDNA was isolated from human fetal
brain RNA by RT-PCR with Thermoscript RT (Invitrogen)
and Platinum Taq DNA polymerase (Invitrogen) and cloning ei-
ther in pCMV-HA or pCMV-myc vectors (CLONTECH Labo-
ratories, Inc.). All constructs were verified by sequencing.
293T, HeLa, and cos-7 cells were grown in Dulbecco’s modi-
fied Eagle’s medium containing 10% fetal calf serum. Cells were
transfected using the standard calcium phosphate method (16) or
Lipofectamine 2000 reagent (Invitrogen).
 
Coimmunoprecipitation.
 
293T cells were cotransfected with the
indicated expression plasmids for CYLD and TRIP. Cells were
lysed 36 h after transfection in RIPA buffer (50 mM Tris-HCl,
pH 7.4, 1% NP-40, 10 mM NaF, 0.25% deoxycholate, 150 mM
NaCl, 1 mM EDTA, 1 mM PMSF, and protease inhibitors;
Roche). The supernatant after centrifugation was used for immu-
noprecipitations with anti-FLAG antibody and protein G–sepha-
rose beads. Beads were washed several times in RIPA buffer. Im-
munoprecipitates were analyzed by immunoblot using FLAG M2
(Sigma-Aldrich), HA (Y-11; Santa Cruz Biotechnology, Inc.), or
myc (A-14; Santa Cruz Biotechnology, Inc.) antibodies.
 
Far Western.
 
TRIP cDNA and fragments thereof were sub-
cloned into the pGEX-4T1 vector (Pharmacia) to generate glu-
tathione 
 
S
 
-transferase (GST) fusion proteins by induction with
0.1 mM IPTG in BL21 CodonPlus (DE3) RIL bacteria. Equal
amounts of protein were separated by SDS-PAGE and trans-
ferred to Hybond membranes. After blocking overnight at 4
 

 
C
in AC buffer (10% glycerol, 100 mM NaCl, 20 mM Tris-HCl,
pH 7.6, 0.5 mM EDTA, 0.1% Tween-20, 2% nonfat dry milk),
membranes were incubated for 2 h with a RIPA buffer extract
from transfected 293T cells diluted in AC buffer. After rinsing
the membrane in 20 mM Tris-HCl, pH 7.5, 100 mM NaCl,
and 0.1% Tween-20, bound proteins were detected as described
above.
 
Immunofluorescence Microscopy.
 
Cells were grown on coverslips
in 6-well plates and transfected as described above. 24–48 h after
transfection, cells were fixed in 
 

 
20
 

 
C methanol for 3 min and
rehydrated in TBST (0.15 M NaCl, 0.02 M Tris-HCl, pH 7.4,
0.1% Triton X-100). Slides were blocked (TBST, 2% BSA) and
incubated with the indicated primary antibodies. Coverslips were
then incubated with biotinylated horse anti–mouse IgG, and fi-
nally with Alexa Fluor 488 goat anti–rabbit IgG F(ab
 

 
)
 
2 
 
fragment
and streptavidin Texas red. Fluorescence images were collected
with a DMIRBE TCSNT laser confocal microscope (Leica). No
cross talk between the green and red channel was detected.
 
NF-
 

 
B Reporter Assay.
 
HeLa or 293T cells seeded (8 
 
	 
 
10
 
4
 
cells/well) in 24-well plates were transfected 24 h later with 0.6
 

 
g of the indicated expression plasmids, and 0.2 
 

 
g pKB-luc
(17) and 0.01 
 

 
g pRL-TK (Promega) as reporter plasmids. Hu-
man TNF-
 
 
 
(R&D Systems) or human IL-1
 
 
 
(Apotech) were
added as indicated. Cell extracts in Passive Lysis Buffer (Pro-
mega) were prepared at the indicated time points and luciferase
activities were measured with the Dual-Luciferase Reporter As-
say System (Promega). Fold induction (mean 
 

 
 
SEM) was calcu-
lated as the ratio of relative luciferase activity from treated and
nontreated samples.
 
Results and Discussion
 
CYLD Interacts with the COOH-terminal Domain of
TRIP.
 
To determine the signal transduction pathways in
which CYLD participates, we performed a yeast two hy-
brid screen using full-length CYLD cDNA as bait and an
HaCaT cDNA library (CLONTECH Laboratories, Inc.) as
Figure 1. Schematic overview of CYLD–TRIP inter-
actions obtained from yeast two hybrid analysis. The inter-
action strength between full-length and subdomains of
CYLD and TRIP was assessed by measuring -galactosidase
activity in the medium. TRIP-N corresponds to aa 1–289,
TRIP-C to aa 290–469, and pACT2–17 to aa 211–469,
respectively. The black box denotes the RING domain,
the hatched box denotes the coiled coil region, and the
punctuate box denotes the leucine zipper domain of
TRIP (reference 18).
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prey. Multiple cDNA clones representing different proteins
were isolated and characterized by sequencing. One of
them, clone pACT2-17, encoded aa 211–469 of TRIP
(TRAF-interacting protein; reference 18). The NH
 
2
 
-ter-
minal half of TRIP contains a RING finger domain, coiled
coil region, and a leucine zipper, and interacts with the
TRAF domain of TRAF1 and TRAF2 (18).
To map interacting domains of TRIP and CYLD and
assess their binding strength we measured 
 

 
-galactosidase
activities. The combination of full-length CYLD with ei-
ther pACT2-17 or full-length TRIP had similar 
 

 
-galac-
tosidase activities, indicating that only the COOH-terminal
part (aa 211–469) of TRIP is required for interacting with
CYLD. To define more precisely the region of TRIP
Figure 2. Analysis of the interaction between CYLD
and TRIP. (A) Ponceau S staining (left) shows loading of
total bacterial extracts expressing GST (lane 1) and GST-
TRIP (lane 2), and RIPA extracts from 293T cells either
nontransfected (lane 3) or transfected with HA-CYLD
(lane 4). Far Western analysis after incubating membrane
with extracts from 293T cells transfected with HA-CYLD
(middle) or nontransfected (right). Bound proteins were
detected with anti-HA antibody. Bars indicate molecular
weights of 100, 50, and 20 kD (top to bottom). (B) Ponceau
S staining (left) shows loading of total bacterial extracts
expressing GST-TRIP-N (lane 1, arrow) and GST-
TRIP-C (lane 2, arrowhead). Far Western analysis with
extracts from 293T cells transfected either with HA-
CYLD (middle) or HA-lacZ (right). Bound proteins were
detected with anti-HA antibody. Bars indicate molecular
weights of 60 and 40 kD (top to bottom). (C) Coimmu-
noprecipitation experiments demonstrate interaction of
CYLD with TRIP-C in 293T cells. Cells were transfected
with equal amounts of FLAG-CYLD and HA-TRIP-C
expression vectors. Immunoprecipitates (lanes 2 and 4) obtained with anti-FLAG antibody were analyzed by Western blots with anti-HA (top) and anti-
FLAG (bottom) antibodies. Lanes 1 and 3 show input. The bars on the right side mark the molecular weights of 20 (top) and 120 kD (bottom).
Figure 3. CYLD and TRIP are colocalized in perinuclear compartment of cos-7 cells. Cells were cotransfected with myc-TRIP and FLAG-CYLD
and their cellular localization was analyzed by staining with anti-FLAG (red) and anti-myc (green) antibodies and confocal immunofluorescence microscopy.
Two examples for CYLD (A and D), TRIP staining (B and E), and the merged pictures (C and F) are shown. Bar, 20 m. Sections are 0.081 m.
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binding to CYLD, we constructed pGADT7 expression
vectors for TRIP-N (aa 1–289) and TRIP-C (aa 290–
469). Only TRIP-C interacted positively with full-length
CYLD, suggesting that the last 179 aa of TRIP carry the
CYLD binding site (Fig. 1). Furthermore, only the central
domain (aa 106–593) but neither N-(aa 1–132) nor C-(aa
558–956) terminal domains of CYLD interacted with full-
length TRIP. These results were confirmed by analyzing
colony formation and blue color of the different combina-
tions of domains on high stringency plates.
To confirm the CYLD–TRIP interaction in mammalian
cells we performed Far Western analysis with GST-TRIP
fusion proteins and cell extracts of 293T cells transfected
with HA-tagged full-length CYLD. Consistent with the
findings in yeast, CYLD bound to GST-TRIP (Fig. 2 A)
and GST-TRIP-C (Fig. 2 B), but not to GST-TRIP-N or
GST. HA-lacZ did not bind to GST-TRIP-C (Fig. 2 B),
indicating that CYLD binding to TRIP-C is specific.
Coimmunoprecipitation experiments with anti-FLAG an-
tibody demonstrated that HA-TRIP-C interacted with
FLAG-CYLD, whereas TRIP-C was not precipitated in
the absence of FLAG-CYLD (Fig. 2 C). Whether full-
length TRIP is immunoprecipitated by CYLD could not
be tested because most of the overexpressed TRIP was not
soluble in the RIPA buffer used for coimmunoprecipita-
tions. Collectively, these experiments established the inter-
action of the central domain of CYLD with the COOH-
terminal portion of TRIP (Fig. 1).
 
CYLD and TRIP Colocalize in the Perinuclear Compart-
ment.
 
Confocal immunofluorescence analysis of cos-7
cells overexpressing FLAG-CYLD and myc-TRIP showed
good colocalization of the two proteins in the perinuclear
region (Fig. 3). An identical staining pattern was observed
in cos-7 cells expressing either CYLD or TRIP, suggesting
that CYLD–TRIP interaction does not change their sub-
cellular localizations.
 
CYLD Inhibits TNF-
 

 
–mediated NF-
 

 
B Activation.
 
The identification of TRIP, which down-regulates TNF-
 

 
–induced NF-
 

 
B activity (18), as CYLD interactor,
prompted us to study the effect of CYLD on NF-
 

 
B acti-
vation. NF-
 

 
B reporter assays in HeLa cells transiently
transfected with pCruzCYLD1 or pHATRIP showed that
CYLD inhibited in a dose-dependent manner TNF-
 

 
–
mediated activation of the NF-
 

 
B reporter gene similar to
TRIP (Fig. 4 A). In contrast, transfection of COOH-ter-
minal truncated CYLD mutants TT14 (aa 1–481) and
TT19 (aa 1–558; reference 9), as well as the mutant
del153–536, where most of the central portion of CYLD
was deleted, showed no effect on TNF-
 
 
 
up-regulation of
NF-
 

 
B activity (Fig. 4 B). This provides evidence that
both the deubiquitinating activity and the central domain,
which interacts with TRIP, are required for CYLD repres-
sion of NF-
 

 
B activation.
Recently, it has been reported that CYLD inhibits the
activation of NF-
 

 
B by IL-1
 
 
 
in 293T cells (19). How-
ever, earlier reports indicated that TRIP does not regulate
the activation of NF-
 

 
B by IL-1
 
 
 
in 293 cells (18). Exper-
iments to reinvestigate whether TRIP affected the IL-1
 

 
activation of NF-
 

 
B clearly showed that TRIP repressed
NF-
 

 
B activation in 293T and HeLa cells (Fig. 4 C and
unpublished data). We conclude that CYLD and TRIP
probably cooperate in the regulation of the IL-1
 
 
 
pathway
in some but not all cell lines. Because CYLD is not inter-
acting with TRAF6 (19), it will be interesting to explore
whether TRIP interacts with TRAF6.
Interestingly, CYLD interacts with NEMO (IKK
 

 
; ref-
erences 19–21) and TRAF2 (19, 21), both of which are
recruited to the TNF receptor upon ligand binding. Fur-
thermore, CYLD inhibits NF-
 

 
B activation by TNF
and TLR/IL-1 family members (19–21). Mechanistically,
CYLD removes lysine-63–linked ubiquitin chains from
TRAF2, TRAF6, and NEMO, whereas lysine-48–linked
ubiquitin chains are not degraded by CYLD (19–21). This
deubiquitinating activity is required for CYLD inhibition
of NF-
 

 
B activation (19–21) and is likely affected by muta-
tions found in cylindroma patients. The removal of the
Figure 4. CYLD and TRIP inhibit cytokine-mediated activation of
NF-B. HeLa (A and B) or 293T (C) cells were treated with 10 ng/ml
TNF- for 20 h or IL-1 for 6 h (at concentrations indicated in ng/ml).
(A) Dose-dependent effect of CYLD on NF-B activation by TNF-.
(B) Effect of CYLD mutants (0.6 g plasmid) TT14, TT19, and del153-
536 on NF-B activity induced by TNF-. (C) TRIP (0.6 g plasmid)
inhibits IL-1 activation of NF-B. The results from one representative
experiment from a total of three (A) or two (B and C) experiments are
shown. Each data point was performed in triplicate.
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ubiquitin moieties by CYLD presumably prevents the as-
sembly of a multiprotein complex activating IKK and sub-
sequently NF-
 

 
B.
The COOH-terminal domain of TRIP interacts with
CYLD, whereas the NH
 
2
 
-terminal region binds to TRAF2
(18). This argues for the presence of a ternary complex of
CYLD, TRIP, and TRAF2, which would block NF-
 

 
B
activation by sequestering TRAF2 away from the TNF re-
ceptor. Physiologically there might be a finely tuned bal-
ance between TRIP and TRAF2 levels deciding whether
there is an excess of TRAF2 and activation of NF-
 

 
B or an
excess of TRIP and no activation. Although it has not been
formally shown that TRIP is ubiquitinated and degraded
by the proteasome upon receptor activation, the RING
domain of TRAF2 could ubiquitinate TRIP. CYLD could
stabilize TRIP by removing the ubiquitins and thereby
blocking NF-
 

 
B activation. This model is supported by re-
porter assays (Fig. 4 B) demonstrating a requirement for the
TRIP-interacting and ubiquitin-specific protease domain
of CYLD to down-regulate NF-
 

 
B.
How do these findings explain cylindroma formation
and the tissue-specific predisposition of this adnexal tumor
despite the ubiquitous tissue expression of CYLD? Inacti-
vation of the CYLD gene should result in persistent activa-
tion of NF-
 

 
B in targeted cells. Although up-regulated
NF-
 

 
B activity leads to cancer in other tissues (22), the sit-
uation in skin is more complex. Sustained NF-
 

 
B activity
in the basal cell layer decreased cell proliferation (23) and
mice where NF-
 

 
B activity is permanently inhibited by
overexpressing degradation-resistant I
 

 
B
 
 
 
develop squa-
mous cell carcinomas (24) or hyperplastic epithelium (23).
Furthermore, coexpression of an oncogenic Ras mutant
and the mutant I
 

 
B
 
 
 
cooperated to form highly invasive
squamous cell carcinomas in human epidermal keratinocyte
grafts (25). These data imply that inhibition not activation
of NF-
 

 
B can lead to epidermal proliferation and neoplas-
tic transformation. However, expression of I
 
B super-
repressor in hair follicles and epidermal appendages and re-
sults from transgenic mice expressing -galactosidase under
the control of NF-B are consistent with a requirement for
NF-B activation in hair follicle and eccrine gland forma-
tion (23, 24, 26, 27). The complex epidermal phenotype
displayed by IB repressor mice is almost identical to
those of tabby, downless, and crinkled mice carrying muta-
tions in the genes for EDA, EDAR, and EDARADD, sug-
gesting that NF-B activity is required for EDA/EDAR
signaling in hair follicle and epidermal appendage forma-
tion (28). In humans, congenital deficiencies of sweat
glands and hair are known in patients suffering from hypo-
or anhydrotic ectodermal dysplasia, which are caused by
mutations in EDAR or EDA genes (29, 30). CYLD de-
presses NF-B activity induced by EDAR and XEDAR
(19, 21), suggesting that loss of CYLD function leads to
increased NF-B signaling, cell proliferation, and up-reg-
ulation of antiapoptotic factors in apocrine cells of the
skin where cylindromas arise (1, 2). Furthermore, TRIP
together with CYLD could negatively regulate EDA/
EDAR/EDARADD signaling because EDARADD inter-
acts with TRAF1, TRAF2, and TRAF3 (28). Preliminary
data from RT-PCR demonstrated that TRIP is expressed
in scalp skin, human foreskin, and epidermis.
In summary, we have identified TRIP as interactor of
CYLD and show that CYLD inhibits NF-B activation
by TNF-. The implication of the interacting pair
CYLD–TRIP in NF-B signaling adds more players to
the already highly complex regulation of NF-B activity
influencing proliferation and differentiation of epidermis
and skin appendages.
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